We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.09B
1-Year Est. Return 112.84%
This Fund
S&P 500
This Quarter Est. Return
+15.65%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$515M
AUM Growth
+$28.6M
Cap. Flow
+$7.92M
Cap. Flow %
1.54%
Top 10 Hldgs %
33.78%
Holding
87
New
22
Increased
22
Reduced
21
Closed
22

Top Buys

Rank Stock Value
1
BAX icon
Baxter International
BAX
+$18.1M
2
BSX icon
Boston Scientific
BSX
+$14M
3
CAH icon
Cardinal Health
CAH
+$12.7M
4
BIIB icon
Biogen
BIIB
+$10.6M
5
CRSP icon
CRISPR Therapeutics
CRSP
+$10.1M

Top Sells

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$15.5M
2
LLY icon
Eli Lilly
LLY
+$15.2M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$14.2M
4
ELV icon
Elevance Health
ELV
+$13.3M
5
DXCM icon
DexCom
DXCM
+$12.4M

Sector Composition

Rank Sector Weight
1 Healthcare 95.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GH icon
1
Guardant Health
GH
$21.4B
$24.2M 4.71%
450,000
+64,709
+17% +$3.32M
CYTK icon
2
CALL
Cytokinetics
CYTK
$10.7B
$22.1M 4.29%
+456,300
New +$22M
ELV icon
3
Elevance Health
ELV
$82B
$18.2M 3.53%
40,000
-27,840
-41% -$13.3M
CNC icon
4
Centene
CNC
$31.7B
$17.5M 3.4%
225,000
-125,000
-36% -$11.2M
CYTK icon
5
Cytokinetics
CYTK
$10.7B
$17M 3.29%
350,000
-175,000
-33% -$8.42M
BAX icon
6
Baxter International
BAX
$14.7B
$16.2M 3.14%
+300,000
New +$18.1M
MRK icon
7
Merck
MRK
$316B
$15.9M 3.09%
185,000
+80,631
+77% +$7.2M
NVST icon
8
Envista
NVST
$4.55B
$14.4M 2.8%
440,000
+53,835
+14% +$2.04M
CRSP icon
9
CRISPR Therapeutics
CRSP
$5.23B
$14.4M 2.79%
220,000
+139,990
+175% +$10.1M
ALNY icon
10
Alnylam Pharmaceuticals
ALNY
$29.3B
$14M 2.72%
70,000
+23,034
+49% +$4.39M
SAGE
11
DELISTED
Sage Therapeutics
SAGE
$14M 2.72%
357,000
-55,257
-13% -$2.14M
BSX icon
12
Boston Scientific
BSX
$71.1B
$13.6M 2.63%
+350,000
New +$14M
RLAY icon
13
Relay Therapeutics
RLAY
$4.26B
$13.4M 2.61%
600,000
+163,738
+38% +$3.59M
BIIB icon
14
Biogen
BIIB
$30.8B
$13.3M 2.59%
+50,000
New +$10.6M
CAH icon
15
Cardinal Health
CAH
$54.7B
$13.3M 2.59%
+200,000
New +$12.7M
CVS icon
16
CVS Health
CVS
$133B
$12.4M 2.41%
130,000
-10,898
-8% -$1.08M
ZNTL icon
17
Zentalis Pharmaceuticals
ZNTL
$347M
$11.9M 2.31%
550,000
+209,757
+62% +$5.74M
PRGO icon
18
Perrigo
PRGO
$1.49B
$11.4M 2.22%
320,000
+137,355
+75% +$5.52M
MCK icon
19
McKesson
MCK
$97.2B
$10.2M 1.98%
30,000
-11,748
-28% -$4.08M
NBIX icon
20
Neurocrine Biosciences
NBIX
$16.9B
$9.56M 1.86%
+90,000
New +$9.13M
SNY icon
21
Sanofi
SNY
$102B
$9.51M 1.85%
250,000
-100,000
-29% -$4.46M
BMRN icon
22
BioMarin Pharmaceuticals
BMRN
$11.7B
$9.07M 1.76%
107,000
-19,286
-15% -$1.72M
PTCT icon
23
PTC Therapeutics
PTCT
$5.77B
$8.18M 1.59%
163,000
+58,344
+56% +$2.86M
QURE icon
24
uniQure
QURE
$3.03B
$8.12M 1.58%
433,000
+79,894
+23% +$1.68M
LLY icon
25
Eli Lilly
LLY
$995B
$8.08M 1.57%
25,000
-48,059
-66% -$15.2M
1
2 3 4

Similar funds

CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
ACM
Analog Century Management New York $2.09B AUM 186.85% 1-Year Est. Return
NSCM
New South Capital Management Memphis, Tennessee $2.09B AUM 33.67% 1-Year Est. Return
ACG
Aventail Capital Group New York $2.09B AUM 43.81% 1-Year Est. Return
NSUP
NLB Skladi upravljanje premozenja Ljubljana $2.09B AUM
TP
Third Point New York $2.08B AUM 27.04% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.08B AUM
TA
TruWealth Advisors Metairie, Louisiana $2.08B AUM 21.15% 1-Year Est. Return

Integral Health Asset Management's Q3 2022 Portfolio in Review

As of Q3 2022, Integral Health Asset Management held 87 positions worth $515M, up 5.9% from $486M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Integral Health Asset Management's Q3 2022 filing shows 22 new, 22 increased, 21 reduced and 22 closed positions. Its largest new stake was Baxter International: 300,000 shares worth $16.2M. The largest sale was AstraZeneca, an estimated $15.5M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier.

  • Integral Health Asset Management's largest Q3 2022 buy was Baxter International: 300,000 shares worth $16.2M.
  • Integral Health Asset Management added most to CRISPR Therapeutics in Q3 2022, an estimated $10.1M increase.
  • Integral Health Asset Management's biggest Q3 2022 reduction was Eli Lilly, cutting an estimated $15.2M.
  • Integral Health Asset Management fully exited AstraZeneca in Q3 2022, selling an estimated $15.5M.
  • Integral Health Asset Management's ten largest holdings make up 34% of its $515M portfolio in Q3 2022.
  • Integral Health Asset Management opened 22 new positions and closed 22 in Q3 2022.
  • Integral Health Asset Management's portfolio value rose 5.9% quarter-over-quarter to $515M.

Based on Integral Health Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.